Volume 20, Issue 46, 2026 (Forthcoming Issue)

About the Cover

Silver nanoparticles are expected to play an important role in solving the problem of multi-drug resistant bacteria emergence in the healthcare sector. Silver nanoparticles are synthesized in various ways, but the preparation of silver nanoparticles using biomass has attracted the attention of many researchers. The preparation of nanoparticles by biological method has many advantages such as low cost, simple fabrication process and environmental safeness. Propolis has been widely used as a folk medicine in the world since ancient times because of their high antimicrobial, antiviral, antioxidant and anti-inflammatory activities. Especially, the bio-synthesized metallic nanoparticles using the Propolis extract could be used to prevent and cure many bacterial and viral diseases due to synergistic effect of antimicrobial and antiviral activity of the propolis extract and the metallic nanoparticles. In this paper, we synthesized Ag nanoparticles by bio-reduction method using Propolis extract. The Surface Plasmon Resonance property of manufactured Ag nanoparticles was 422 nm, the average particle size was 10nm and the zeta potential value was -36.3mV.

Previous

ARTICLE

Green Synthesis of Propolis-Ag Nanoparticles Using the Propolis Extract and Their Antimicrobial Activity

Song-Sik Kim, Song-Jin Pak, Chol-Hong, Chol-Jin Hwang, Kwang-Il To, Su-Chol Rim, Jong-Chol Son, Il-Song Pang

Silver nanoparticles are expected to play an important role in solving the problem of multi-drug resistant bacteria emergence in the healthcare sector. Silver nanoparticles are synthesized in various ways

Drug Discovery, 2026, 20(45), e16dd3093

Abstract | PDF

Ensemble docking and molecular dynamics validation of quinazoline c9 targeting mutant kras(g12c)

Stephen Adebayo Osasan, George Oche Ambrose, Olusola Daramola, Oluwafemi Ayodele Adefolalu, Alzahrani A. Hind, Mohammad Alshehri Jawaher, Wisdom Onuche Ibrahim, Olanrewaju I Ajetunmobi

The KRAS(G12C) mutations represent a major oncogenic driver in multiple types of cancer. Covalent inhibitors such as sotorasib have shown clinical efficacy, but identifying alternative scaffolds that can stabilise the Switch-II pocket

Drug Discovery, 2026, 20(45), e17dd3099

Abstract | PDF